Ovoca Bio is a clinical-stage biopharmaceutical company dedicated to advancing women's health, particularly through the development of Orenetide, a novel synthetic peptide aimed at treating hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is a prevalent condition affecting approximately 4 million women in both the US and Europe, characterized by a distressing lack of sexual desire. Orenetide is administered via a nasal spray, which allows the drug to target olfactory and trigeminal nerves, leading to accumulation in the olfactory bulb and subsequent effects in the brain. The company has successfully completed Phase II and III clinical trials in Russia, demonstrating significant improvements in sexual desire and satisfaction among participants, alongside a favorable safety profile.

In addition to its focus on Orenetide, Ovoca Bio is committed to expanding its patent portfolio to protect its innovative technologies and product candidates. The company aims to establish itself as a leader in the research and development of novel medicines that address high unmet medical needs in women's health. Ovoca Bio is actively seeking opportunities for collaboration and licensing with global pharmaceutical companies to expedite the availability of its treatments. The ongoing validation of Orenetide's efficacy in major markets, including Europe and the US, underscores the company's dedication to addressing the significant challenges faced by women suffering from HSDD.

Ireland

Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women’s health. The Company is currently developing a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire. The Society for Women’s Health Research estimates that about one in ten premenopausal women suffer from HSDD, making it one of the most common female sexual problems.

Ovoca Bio

Company Details